Biocompatibles gains pivotal drug delivery patent
This article was originally published in Clinica
Executive Summary
Following the high profile share price meltdown of UK stent manufacturer Biocompatibles International (see Clinica No 965, p 1), the company was almost silent over the granting of a pivotal US patent for doping its PC coating with heparin.